Clin Lab. 2022 Jun 1;68(6). doi: 10.7754/Clin.Lab.2021.211012.
This study aimed to investigate the effect of the COVID-19 pandemic on urine culture results and antibiotic sensitivities in patients with suspected urinary tract infections (UTI) admitted to the emergency department (ED) and determine more accurate treatment modalities for patients. The primary endpoint of our study was to determine the change in antibiotic resistance of UTI agents in the pre-and post-COVID period.
In the study, urine samples were sent from ED to the microbiology laboratory with a preliminary diagnosis of UTI between June 1, 2019, and July 1, 2021. Urine samples with the growth of 105 cfu/mL and above in urine cultures or with the growth of 103 cfu/mL and above in urine sample cultures taken from catheters were examined. At the end of the exclusions, the results of a total of 1,090 patients were evaluated. Urine cultures and an-tibiotic susceptibility tests of the patients included in the study were examined in two periods (pre-pandemic and post-pandemic).
A total of 1,090 aerobic urine cultures sent from the ED between June 2019 and June 2021 were finalized in the microbiology laboratory. Of the 1,090 urine cultures sent from the ED within the 24 months included in the study, 497 (45.59%) were sent eight months before the COVID-19 pandemic. Growth was detected in 33 (6.63%) cultures. In the 16 months after the pandemic, 593 (54.41%) urine cultures were sent. Growth was seen in 69 (11.6%) cultures. The positivity rate obtained from urine cultures sent after the COVID-19 pandemic was significantly higher than those sent before the COVID-19 pandemic (p = 0.005). According to cultures and antibiogram results, resistance to ampicillin, cefuroxime, cefuroxime axetil, cefoxitin, cefixime, ceftazidime, ceftriaxone, and amoxicillin-clavulanic acid decreased significantly compared with pre-COVID-19 (p < 0.05). In addition, Extended Spectrum Beta-Lactamase (ESBL) resistance decreased significantly compared with the prepandemic period (p = 0.012).
In this study, we found that the susceptible to antibiotics increased significantly in the post-COVID-19 period compared to the pre-COVID-19 period.
本研究旨在探讨 COVID-19 大流行对急诊科疑似尿路感染（UTI）患者的尿液培养结果和抗生素敏感性的影响，并确定更准确的治疗方法。我们研究的主要终点是确定 COVID-19 前后 UTI 病原体的抗生素耐药性变化。
在这项研究中，2019 年 6 月 1 日至 2021 年 7 月 1 日期间，从急诊科向微生物学实验室送检初步诊断为 UTI 的尿液样本。对尿液培养物中生长 105 cfu/mL 及以上或导管中采集的尿液样本中生长 103 cfu/mL 及以上的尿液样本进行检查。在排除结束后，共评估了 1090 名患者的结果。对纳入研究的患者的尿液培养物和抗生素药敏试验进行了两个时期（大流行前和大流行后）的检查。
在微生物学实验室中完成了 2019 年 6 月至 2021 年 6 月期间从急诊科送检的 1090 份需氧尿液培养物。在研究期间的 24 个月内，从急诊科送检的 1090 份尿液培养物中，有 497 份（45.59%）是在 COVID-19 大流行前 8 个月送检的。培养物中检测到 33 例（6.63%）生长。大流行后 16 个月，送检 593 份（54.41%）尿液培养物。培养物中发现 69 例（11.6%）生长。COVID-19 大流行后送检的尿液培养物阳性率明显高于 COVID-19 大流行前（p=0.005）。根据培养物和药敏试验结果，与 COVID-19 前相比，氨苄西林、头孢呋辛、头孢呋辛酯、头孢西丁、头孢克肟、头孢他啶、头孢曲松和阿莫西林克拉维酸的耐药性显著降低（p<0.05）。此外，与大流行前相比，产超广谱β-内酰胺酶（ESBL）的耐药性显著降低（p=0.012）。
在这项研究中，我们发现与 COVID-19 大流行前相比，COVID-19 大流行后抗生素的敏感性显著增加。
